Do Not Add Cefuroxime to Azithromycin
Adding cefuroxime to azithromycin is not recommended and represents a fundamental misunderstanding of antibiotic management for acute bacterial rhinosinusitis (ABRS). The patient has already failed azithromycin and is currently on the correct therapy—high-dose amoxicillin-clavulanate—which should be continued.
Why This Approach Is Wrong
Azithromycin Has Already Failed
- Azithromycin is not a first-line agent for ABRS according to IDSA guidelines 1
- The patient has already demonstrated treatment failure with azithromycin
- Adding another antibiotic to a failed regimen makes no therapeutic sense
- The failed antibiotic should be discontinued, not supplemented
Current Therapy Is Appropriate
The 2012 IDSA guidelines explicitly recommend high-dose amoxicillin-clavulanate (2g twice daily) as the treatment of choice for ABRS 1. The 2025 AAO-HNS guidelines updated this to recommend "amoxicillin with or without clavulanate" as first-line therapy 2. Since this patient failed azithromycin (an inappropriate initial choice), they are now correctly receiving high-dose amoxicillin-clavulanate.
Cefuroxime Is Not Indicated Here
- Cefuroxime is FDA-approved for lower respiratory infections, UTIs, skin infections, septicemia, meningitis, gonorrhea, and bone/joint infections 3
- Sinusitis is notably absent from its FDA-approved indications
- While some older research suggests cefuroxime has comparable efficacy to amoxicillin-clavulanate 4, it would be used as an alternative, not as an addition
- Dual beta-lactam therapy (amoxicillin-clavulanate + cefuroxime) provides no additional coverage and only increases side effects and cost
What Should Actually Be Done
If Currently on High-Dose Amoxicillin-Clavulanate
- Continue the current regimen for the full 5-7 day course 1
- Monitor for clinical improvement over 48-72 hours
- If no improvement after 72 hours on appropriate therapy, consider:
- Imaging (CT scan) to assess for complications
- Referral to ENT for possible drainage or alternative diagnosis
- Culture-directed therapy if sinus aspirate obtained
If Treatment Fails After Completing Amoxicillin-Clavulanate
Switch to a respiratory fluoroquinolone (levofloxacin or moxifloxacin), which provides broader coverage including resistant organisms 1, 5, 6. This represents true second-line therapy, not adding antibiotics together.
Key Clinical Pitfalls
Polypharmacy trap: Adding antibiotics together without clear indication increases adverse effects (particularly diarrhea, which occurs in 17-32% with amoxicillin-clavulanate alone 7, 8) without improving outcomes.
Duration matters: Adults with ABRS need only 5-7 days of appropriate antibiotic therapy 1. Ensure adequate time on the correct regimen before declaring failure.
Consider non-bacterial causes: If a patient fails multiple appropriate antibiotic regimens, reconsider the diagnosis—chronic rhinosinusitis, fungal sinusitis, or anatomic obstruction may be present 2.